Oncotarget

Research Papers:

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

Junghui Koo _, Xuerong Wang, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri and Shi-Yong Sun

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:8974-8987. https://doi.org/10.18632/oncotarget.3291

Metrics: PDF 1135 views  |   HTML 1268 views  |   ?  


Abstract

Junghui Koo1, Xuerong Wang2, Taofeek K. Owonikoko1, Suresh S. Ramalingam1, Fadlo R. Khuri1, Shi-Yong Sun1

1Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA

2Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, China

Correspondence to:

Shi-Yong Sun, e-mail: ssun@emory.edu

Keywords: GSK3, mTOR, rapamycin, degradation, oncogenic proteins

Received: January 09, 2015     Accepted: February 05, 2015     Published: March 12, 2015

ABSTRACT

The single-agent activity of rapalogs (rapamycin and its analogues) in most tumor types has been modest at best. The underlying mechanisms are largely unclear. In this report, we have uncovered a critical role of GSK3 in regulating degradation of some oncogenic proteins induced by rapalogs and cell sensitivity to rapalogs. The basal level of GSK3 activity was positively correlated with cell sensitivity of lung cancer cell lines to rapalogs. GSK3 inhibition antagonized rapamycin’s growth inhibitory effects both in vitro and in vivo, while enforced activation of GSK3β sensitized cells to rapamycin. GSK3 inhibition rescued rapamcyin-induced reduction of several oncogenic proteins such as cyclin D1, Mcl-1 and c-Myc, without interfering with the ability of rapamycin to suppress mTORC1 signaling and cap binding. Interestingly, rapamycin induces proteasomal degradation of these oncogenic proteins, as evidenced by their decreased stabilities induced by rapamcyin and rescue of their reduction by proteasomal inhibition. Moreover, acute or short-time rapamycin treatment dissociated not only raptor, but also rictor from mTOR in several tested cell lines, suggesting inhibition of both mTORC1 and mTORC2. Thus, induction of GSK3-dependent degradation of these oncogenic proteins is likely secondary to mTORC2 inhibition; this effect should be critical for rapamycin to exert its anticancer activity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3291